Clinical Trial Update: Effect of Nafamostat on Postreperfusion Syndrome (PRS) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluated Nafamostat for effects on postreperfusion syndrome in liver transplant patients; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postreperfusion Syndrome

Drugs mentioned

• Nafamostat (nafamostat mesylate)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Liver Transplantation, Postreperfusion Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2010-05-03